Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review

  • ID: 1322531
  • SWOT Analysis
  • 68 pages
  • GlobalData
  • Shire PLC.
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • MORE
Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analysts summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc Key Recent Developments

Jul 31, 2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress
Jul 25, 2018: Shire announces Director declaration
Jul 17, 2018: argenx receives milestone payment from strategic collaboration with Shire
May 30, 2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
May 02, 2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • Shire Plc - Key Facts
  • Shire Plc - Key Employees
  • Shire Plc - Key Employee Biographies
  • Shire Plc - Major Products and Services
  • Shire Plc - History
  • Shire Plc - Company Statement
  • Shire Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 – Company Analysis
  • Company Overview
  • Shire Plc - Business Description
  • Product Category: Genetic Disease
  • Overview
  • Performance
  • Product Category: Hematology
  • Overview
  • Performance
  • Product Category: Immunology
  • Overview
  • Performance
  • Product Category: Internal Medicine
  • Overview
  • Performance
  • Product Category: Neuroscience
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Ophthalmology
  • Overview
  • Performance
  • Product Category: Royalties and Other Revenues
  • Overview
  • Performance
  • Geographical Segment: Ireland
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Shire Plc - Corporate Strategy
  • Shire Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Shire Plc - Strengths
  • Shire Plc - Weaknesses
  • Shire Plc - Opportunities
  • Shire Plc - Threats
  • Shire Plc - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Shire Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Shire Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jul 31, 2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress
  • Jul 25, 2018: Shire announces Director declaration
  • Jul 17, 2018: argenx receives milestone payment from strategic collaboration with Shire
  • May 30, 2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
  • May 02, 2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference
  • Apr 26, 2018: Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018
  • Mar 22, 2018: Shire Commits to Long-Term Responsibility Goals in 2017 Annual Responsibility Review
  • Mar 13, 2018: Shire Applies to Cease to be a Reporting Issuer in Canada
  • Mar 05, 2018: Shire Launches MyPKFi For Advate In U.S
  • Feb 20, 2018: Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Shire Plc, Key Facts
  • Shire Plc, Key Employees
  • Shire Plc, Key Employee Biographies
  • Shire Plc, Major Products and Services
  • Shire Plc, History
  • Shire Plc, Other Locations
  • Shire Plc, Subsidiaries
  • Shire Plc, Joint Venture
  • Shire Plc, Key Competitors
  • Shire Plc, Ratios based on current share price
  • Shire Plc, Annual Ratios
  • Shire Plc, Annual Ratios
  • Shire Plc, Annual Ratios
  • Shire Plc, Interim Ratios
  • Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Shire Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Shire Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Shire Plc, Performance Chart (2013 - 2017)
  • Shire Plc, Ratio Charts
  • Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Supernus Pharmaceuticals Inc
  • Pfizer Inc
  • Novo Nordisk AS
  • Novartis AG
  • JCR Pharmaceuticals Co Ltd
  • Ferring International Center SA
  • Eli Lilly and Co
  • Bayer AG
  • Actelion Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll